Immune responses of a designed HIV-1 DNA vaccine on rhesus monkeys

详细信息    查看全文

• 作者：Lishu Zhang (1)
  Jin Ningyi (1)
  Song Yingjin (2)
  Sun Yansong (3)
  Wang Hong (4)
  Zhan Dawei (3)
  Hewen Ma (5)
  Yupu Shang (3)
  Hongtao Jin (1)
  Baoqing Hong (3)
  Chang Li (1)
  
• 关键词：HIV ; 1 ; designed ; DNA vaccine ; immune response ; rhesus monkey
• 刊名：Chinese Science Bulletin
• 出版年：2006
• 出版时间：July 2006
• 年：2006
• 卷：51
• 期：13
• 页码：1571-1577
• 全文大小：852KB
• 参考文献：1. State Council AIDS Working Committee Office and UN Theme Group on HIV/AIDS in China. A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (2004). 2004: 4-0.
  2. Palella F J, Delaney K M, Moorman A C, et al. Declining morbidity and mortality among patients with advanced human immunode-ficiency virus infection. Outpatient Study Investigators. New Engl J Med, 1998, 338: 853-60 CrossRef
  3. Mocroft A, Vella S, Benfield T L, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet, 1998, 352: 1725-730 CrossRef
  4. Walmsley S, Bernstein B, King M, et al. Lopinavir: Ritonavir versus nelfinavir for the initial treatment of HIV infection. New Engl J Med, 2002, 346: 2039-046 CrossRef
  5. Daniel M D, Kirchhoff F, Czajak S C, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science, 1992, 258: 1938-941
  6. Cranage M P, Hall G A, Dennis M J, et al. Macaques infected with live attenuated SIV mac are protected against superinfection via the rectal mucosa. Virology, 1997, 229(1): 143-54 CrossRef
  7. Smith S M, Khoroshev M, Marx P A, et al. Constitutively dead, conditionally live HIV-1 genomes. / Ex vivo implications for a live virus vaccine. J Biol Chem, 2001, 276(34): 32184-2190 CrossRef
  8. Stebbings R, Berry N, Stott J, et al. Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology, 2004, 330(1): 249-60 CrossRef
  9. Singh D K, Liu Z, Sheffer D, et al. A noninfectious simian/human immunodeficiency virus DNA vaccine that protects macaques against AIDS. J Virol, 2005, 79(6): 3419-428 CrossRef
  10. Peng J M, Tong G Z, Wang Y F, et al. Multi-epitope DNA vaccines against avian influenza in chickens. Chin J Biotech (in Chinese). 2003, 19(5): 623-27
  11. Wang X H, Tong D Y, Xu H B, et al. Construction and immunogenecity of a multi-epitope sased SARS-CoV gene vaccine. J Shanghai Med Univ (in Chinese), 2005, 32(2): 130-33
  12. Ding J, He F, Lu Y, et al. Induction of multi-epitope-specific anti-bodies against HIV-1 by multi-epitope-vaccine. Chin Sci Bull, 2001, 46(22): 13-8. CrossRef
  13. Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989, 16-8
  14. Li Z J, Jin N Y, Jiang W Z, et al. A new type of multiple-epitope DNA vaccine against HIV. Chin J Microbiol Immunol (in Chinese), 2004, 24(11): 910-13
  15. Walker B D, Korber B T. Immune control of HIV: The obstacles of HLA and viral diversity. Nat Immun, 2001, 2: 473-75 CrossRef
  16. Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull, 2001, 58: 19-2 CrossRef
  17. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science, 2002, 296: 2354-360 CrossRef
  18. Novitsky V, Smith U R, Gilbert P, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: Consensus sequence for an AIDS vaccine design? J Virol, 2002, 76(11): 5435-451 CrossRef
  19. Williamson A L, Marais D, Passmore J A, et al. Human papillomavirus (HPV) infection in Southern Africa: Prevalence, immunity, and vaccine prospects. IUBMB Life, 2002, 53(4-): 253-58 CrossRef
  20. Mashishi T, Loubser S, Hide W, et al. Conserved domains of subtype C Nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res Hum Retroviruses, 2001, 17(17): 1681-687 CrossRef
  21. Borrow P, Lewicki H, Hahn B H, et al. Virus-specific CD8⁺ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol, 1994, 68(9): 6103-110
  22. Koup R A, Safrit J T, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol, 1994, 68(7): 4650-655
  23. Rosenberg E S, Billingsley J M, Caliendo A M, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science, 1997, 278: 1447-450 CrossRef
  24. Ogg G S, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science, 1998, 279: 2103-106 CrossRef
  25. Gea-Banacloche J C, Migueles S A, Martino L, et al. Maintenance of large numbers of virus-specific CD8⁺ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol, 2000, 165: 1082-092
  26. Chouquet C, Autran B, Gomard E, et al. Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS, 2002, 16: 2399-407 CrossRef
  27. Barouch D H, Santra S, Kuroda M J, et al. Reduction of simian-human immunodeficiency virus 89. 6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol, 2001, 75(11): 5151-158 CrossRef
  28. Amara R R, Villinger F, Altman J D, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science, 2001, 292: 69-4 CrossRef
  29. Shiver J W, Fu T M, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature, 2002, 415: 331-35 CrossRef
  30. Horton H, Vogel T U, Carter D K, et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus(SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIV mac239. J Virol, 2002, 76(14): 7187-202 CrossRef
  31. Allen T M, O’Connor D H, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature, 2000, 407: 386-90 CrossRef
  32. Barouch D H, Kunstman J, Kuroda M J, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature, 2002, 415: 335-39 CrossRef
  33. Vogel T U, Friedrich T C, O’Connor D H, et al. Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: A paradigm for virus evolution and persistence? J Virol, 2002, 76(22): 11623-1636 CrossRef
  34. Nacsa J, Stanton J, Kunstman K J, et al. Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251. Virology, 2003, 305(1): 210-18 CrossRef
  35. Romagnai S. Human Th1 and Th2 subsets: dout no more. Immunol Today, 1991, 12: 256-57 CrossRef
  36. Adorini L, Sinigaglia F. Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today, 1997, 18: 209-11 CrossRef
  37. Romagnani S. The Th1/Th2 paradigm. Immunol Today, 1997, 18: 263-66 CrossRef
  38. Clerici M, Shearer G M. A Th1→Th2 switch is a critical step in the etiology of HIV infection. Immunol Today, 1993, 14: 107-11 CrossRef
  39. Clerici M, Sarin A, Coffman R L, et al. Type 1/type 2 cytokine modulation of T-cell programed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA, 1994, 91: 11811-1815 CrossRef
  40. Clerici M, Lucey D R, Berzofsky J A, et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science, 1993, 262: 1721-724
  
• 作者单位：Lishu Zhang (1)
  Jin Ningyi (1)
  Song Yingjin (2)
  Sun Yansong (3)
  Wang Hong (4)
  Zhan Dawei (3)
  Hewen Ma (5)
  Yupu Shang (3)
  Hongtao Jin (1)
  Baoqing Hong (3)
  Chang Li (1)
  
  1. The 11th Institute, Academy of Military Medical Sciences, Changchun, 130062, China
  2. College of Agricultural and Biological Engineer, Tianjin University, Tianjin, 30072, China
  3. Laboratory Animal Center, Academy of Military Medical Sciences, Beijing, 100071, China
  4. College of Life Science, Jinan University, Guangzhou, 510632, China
  5. Agricultural Sciences Center, Jilin University, Changchun, 130062, China
  
• ISSN：1861-9541

文摘

An effective HIV-1 vaccine will be the ultimate solution for the prevention of HIV/AIDS, though HAART plays important roles in treating the disease. In this study, a large-scale recombinant DNA plasmid containing a designed HIV-1 multi-epitope-p24 chimeric gene was prepared and purified. Rhesus monkeys were then inoculated muscularly with the plasmid for four times in week 0, 4, 8 and 18. Whole blood was collected two weeks after the third and fourth inoculation, followed by serum and peripheral blood mononuclear cell (PBMC) separation. The CTL activity and proliferation of PBMCs stimulated by macaque MHC-I-restricted HIV-1 CTL epitope peptide were analyzed by MTT and LDH release assay, respectively. Th1 cytokines in supernatant of cultured PBMC stimulated by HIV-1 CTL epitope peptide and anti-HIV-1 antibody in serum were assayed by ELISA. The results showed that increased CTL target-killing activity, higher secretion of Th1 cytokines (IFN-γ and IL-2) and promoted proliferative reaction of monkey PBMCs stimulated by HIV-1 CTL epitope peptide were detected in the immunization group inoculated by the recombinant DNA vaccine for three times, which were further enhanced by the fourth inoculation. At the same time, HIV-1 specific antibody in serum of immunized monkeys was higher than that in controls. We concluded that the designed HIV-1 DNA vaccine may induce HIV-1 specific cellular and humoral immunity on monkeys.